From cells to purified capsids: How to develop a scalable rAAV process

Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.

Adeno-associated virus (AAV) is the most common vector for gene therapy, yet there’s much room to improve production, purification, and analytics. Here we present the latest updates to our work developing a scalable start-to-finish rAAV process. We produce and purify several serotypes, optimizing each step along the way. The key for a successful process are high overall yields of full capsids with empty capsid reduction and efficient impurity removal.

In this webinar you will learn:

• Common pitfalls for rAAV processing and ways to overcome the challenges
• How the full and empty AAV capsid separation can be significantly improved with one chromatography resin and one protocol for AAV2, AAV5, AAV8 and AAV9

Åsa Hagner McWhirter

Principal Scientist at Cytiva

Åsa holds a PhD in Medical Biochemistry from Uppsala University in 1999. Åsa has been with the company since 2003, working as a Downstream SME, with a broad and deep understanding of biopharmaceutical application challenges in the area of viral vectors and vaccines, as well as general protein purification and analysis.